The story of GraalVM in early 2026: a project settling into a quarterly cadence, tightening its support matrix, and—thanks to Oracle—being very explicit about what it is no longer going to be.

Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...

Clint Proctor is a lead editor with the credit cards and travel rewards team at Forbes Advisor. He has five years of experience in personal finance journalism and has contributed to a variety of ...